GlaxoSmithKline (GSK) is a major British pharmaceutical company specializing in the development and manufacturing of products in infectious diseases, oncology, immunology, and vaccines.
📊 Financial Results for 2024
-
Revenue: £31.4 billion (+3.5% compared to 2023)
-
Net Profit: £2.58 billion (down 48%)
-
Earnings Per Share (EPS): £0.63 (down 48%)
-
Operating Profit: £4.0 billion (down 33%)
-
Core Operating Profit: £9.1 billion (+11% at constant exchange rates)
-
Free Cash Flow: £3.0 billion
Note: The decline in profit was mainly due to one-time expenses of £1.8 billion related to the settlement of lawsuits concerning the Zantac drug. (gsk.com)
💊 Key Areas and Products
-
Specialty Medicines: Sales grew by 19%, including:
-
HIV drugs: +13%
-
Oncology: +98%
-
Respiratory and Immunology medicines: +13%
-
-
Vaccines: Sales decreased by 4%, including:
-
Shingrix (shingles vaccine): +1%
-
Arexvy (RSV vaccine): -51%
-
-
Consumer Healthcare: Sales increased by 6%, including:
-
Trelegy (COPD treatment): +27%
-
🔮 2025 Outlook
-
Revenue Growth: 3–5%
-
Core Operating Profit: Growth of 6–8%
-
Core EPS Growth: 6–8%
-
Dividends: Expected to pay 65 pence per share
-
Share Buyback Program: £2 billion over 18 months
-
Long-term Outlook: Revenue over £40 billion by 2031
🧬 Research and Development
-
R&D Investment: £6.4 billion in 2024
-
Clinical Development: 71 assets in the portfolio, with 19 in phase III or registration stages
-
Upcoming Approvals: 5 major products expected in 2025
📈 Stock Market and Investment
-
Stock Ticker: GSK (London Stock Exchange)
-
Stock Price: Around £14.82 (as of early February 2025)
-
Dividend Yield: Stable, with an expected increase in 2025
Conclusion: GSK shows strong results in specialty medicines and continues to invest heavily in innovation. Despite a decrease in vaccine sales and one-time expenses, the company has a positive outlook for 2025 and a solid long-term growth trajectory.